Skip to main content

Table 4 Endometrial cancer mortality in relation to age at diagnosis, FIGO stage and morphology of endometrial cancer

From: Endometrial cancer survival after breast cancer in relation to tamoxifen treatment: Pooled results from three countries

  Patients Endometrial cancer mortality
  N Deaths HR 95% CI
Age at diagnosis of endometrial cancera
   < 55 190 14 1.00 baseline
   55 to 64 469 51 1.57 0.87, 2.84
   65 to 74 653 87 2.13 1.21, 3.75
   75 to 84 445 92 3.65 2.08, 6.43
   85 and over 118 33 5.69 3.03, 10.7
   Heterogeneity (4 d.f.)    P < 0.0001
   Trend (1 d.f.)    P < 0.0001
FIGO stageb
   I 1016 64 1.00 baseline
   II 132 26 3.34 2.11, 5.28
   III/IV 140 67 13.1 9.25, 18.6
   Unknown 587 120 2.92 2.06, 4.14
   Heterogeneity (3 d.f.)    P < 0.0001
Morphologyc
   Endometrioidd 1580 162 1.00 baseline
   Serous or clear celle 108 32 2.25 1.51, 3.37
   Carcinosarcomaf 108 54 5.41 3.92, 7.45
   Sarcomag 54 20 3.93 2.42, 6.38
   Unknown 25 9 4.11 2.06, 8.14
   Heterogeneity (4 d.f.)    P < 0.0001
All non-endometrioidh 270 106 3.75 2.88, 4.87
Morphology by tamoxifen usec
   Tamoxifen users:     
   - non-endometrioid 190 79 3.32 2.06, 5.35
   -endometrioid 929 105 1.00 baseline
   Tamoxifen non-user     
   - non-endometrioid 80 27 3.88 2.86, 5.28
   -endometrioid 651 57 1.00 baseline
   Heterogeneity interactionh (1 d.f.)    P = 0.57
   Morphology unknown: 25 9   
  1. aAdjusted for time since diagnosis of endometrial cancer, study, calendar period, FIGO stage;
  2. badjusted for time since diagnosis of endometrial cancer, study, calendar period, attained age;
  3. cadjusted for time since diagnosis of endometrial cancer, study, calendar period, FIGO stage, attained age;
  4. d endometrial adenocarcinoma, mixed cell adenocarcinoma, papillary endometrial adenocarcinoma;
  5. eserous adenocarcinoma, clear cell adenocarcinoma; fcarcinosarcoma, Mullerian mesodermal mixed tumors; gsarcoma, endometrial stromal adenocarcinoma, leiomyosarcoma; hExcludes those where morphology was unknown. CI, confidence interval; FIGO, International Federation of Gynaecology and Obstetrics; HR, hazard ratio; N, number.